Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement.

Cancer Med · 2026 · PMC12872283 · PMID 41638230

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

1.0 months, HR = 0.37, 95% CI: 0.10–1.32, p = 0.051) groups, compared to that in the BSC group, but the differences were borderline significant (Figure 2C ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.